Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 7;20(1):101.
doi: 10.1186/s12933-021-01289-4.

Variability of risk factors and diabetes complications

Affiliations
Review

Variability of risk factors and diabetes complications

Antonio Ceriello et al. Cardiovasc Diabetol. .

Abstract

Several studies suggest that, together with glucose variability, the variability of other risk factors, as blood pressure, plasma lipids, heart rate, body weight, and serum uric acid, might play a role in the development of diabetes complications. Moreover, the variability of each risk factor, when contemporarily present, may have additive effects. However, the question is whether variability is causal or a marker. Evidence shows that the quality of care and the attainment of the target impact on the variability of all risk factors. On the other hand, for some of them causality may be considered. Although specific studies are still lacking, it should be useful checking the variability of a risk factor, together with its magnitude out of the normal range, in clinical practice. This can lead to an improvement of the quality of care, which, in turn, could further hesitate in an improvement of risk factors variability.

Keywords: Blood pressure variability; Body weight variability; Cardiovascular complications; Diabetes mellitus; Glucose variability; Heart rate variability; Lipids variability; Microvascular complications; Oxidative stress; Uric acid variability.

PubMed Disclaimer

Conflict of interest statement

Authors do not have conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Recursive partitioning techniques (RECPAM) analysis of developing albuminuria in a cohort of 4231 patients with T2D followed up for a median of 3.4 years and with 5 subsequent measurements of risk factors [36]. The tree-growing algorithm resumes the hazard of developing albuminuria according to a multivariable Cox regression analysis. At each step, the method proceeds forward using the covariate with the highest difference in risk. The algorithm proceeds until user-defined conditions are met. Variables used to build the model were quartiles of variability in HbA1c, systolic blood pressure (SBP) and diastolic blood pressure (DBP), serum uric acid (UA), total, high-density lipoprotein (HDL), low-density lipoprotein (LDL) cholesterol and triglycerides., while additional baseline parameters were considered in the model as global variables, i.e. age, gender, duration of diabetes, smoking, hypertension, baseline HbA1c, blood pressure, UA, lipid parameters and estimated glomerular filtration rate (eGFR) values. The variable determining patient’s assignment to the subsequent group is evidenced on the branch proceeding to the following subgroup, while rectangles represent the REPCAM class. The numbers in the circles and rectangles represent the patients who develop albuminuria compared with the total number of patients in the subgroup, respectively (Reproduced with permission from Ref. [36])
Fig. 2
Fig. 2
RECPAM analysis of developing a decrease in glomerular filtration rate (GFR). The RECPAM tree-growing algorithm models the hazard of developing GFR < 60 mL/min/1.73 m2 using the same approach and the same variables described for Fig. 1 in the same population (Reproduced with permission from Ref. [36])

Similar articles

  • Diabetes, prediabetes and cardiovascular risk.
    Mellbin LG, Anselmino M, Rydén L. Mellbin LG, et al. Eur J Cardiovasc Prev Rehabil. 2010 May;17 Suppl 1:S9-14. doi: 10.1097/01.hjr.0000368192.24732.2f. Eur J Cardiovasc Prev Rehabil. 2010. PMID: 20489420 Review.
  • Sexual dysfunctions in diabetes: a gender issue.
    Maiorino MI, Bellastella G, Esposito K. Maiorino MI, et al. J Diabetes Complications. 2017 May;31(5):785-786. doi: 10.1016/j.jdiacomp.2017.03.001. Epub 2017 Mar 9. J Diabetes Complications. 2017. PMID: 28319007 No abstract available.
  • Treatment Goals in Diabetes.
    Melmer A, Laimer M. Melmer A, et al. Endocr Dev. 2016;31:1-27. doi: 10.1159/000439364. Epub 2016 Jan 19. Endocr Dev. 2016. PMID: 26824869 Review.
  • [Guidelines on diabetes, pre-diabetes, and cardiovascular diseases].
    Grupo de Trabajo sobre Diabetes y Enfermedades Cardiovasculares de la Sociedad Europea de Cardiología y de la Sociedad Europea para el Estudio de la Diabetes; Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I. Grupo de Trabajo sobre Diabetes y Enfermedades Cardiovasculares de la Sociedad Europea de Cardiología y de la Sociedad Europea para el Estudio de la Diabetes, et al. Rev Esp Cardiol. 2007 May;60(5):1e-64e. Rev Esp Cardiol. 2007. PMID: 17535764 Spanish. No abstract available.
  • International Forum for the Advancement of Diabetes Research and Care, April 29-30, 2011, Athens, Greece.
    Bolli GB, Deeb LC, Garg SK, Leahy JL, Mazze RS, Owens DR, Riddle MC, Southerland P, Strock ES. Bolli GB, et al. Diabetes Technol Ther. 2011 Sep;13(9):967-79. doi: 10.1089/dia.2011.0179. Diabetes Technol Ther. 2011. PMID: 21864094 Free PMC article.

Cited by

References

    1. Ceriello A, Monnier L, Owens D. Glycaemic variability in diabetes: clinical and therapeutic implications. Lancet Diabetes Endocrinol. 2019;7:221–230. doi: 10.1016/S2213-8587(18)30136-0. - DOI - PubMed
    1. Ranjan AG, Rosenlund SV, Hansen TW, Rossing P, Andersen S, Nørgaard K. Improved time in range over 1 year is associated with reduced albuminuria in individuals with sensor-augmented insulin pump-treated type 1 diabetes. Diabetes Care. 2020;43(11):2882–2885. doi: 10.2337/dc20-0909. - DOI - PubMed
    1. Hirakawa Y, et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care. 2014;37:2359–2365. doi: 10.2337/dc14-0199. - DOI - PubMed
    1. Zinman B, et al. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2) Diabetologia. 2018;61:48–57. doi: 10.1007/s00125-017-4423-z. - DOI - PMC - PubMed
    1. Zhou JJ, Schwenke DC, Bahn G, Reaven P, VADT Investigators Glycemic variation and cardiovascular risk in the Veterans Affairs Diabetes Trial. Diabetes Care. 2018;41:2187–2194. doi: 10.2337/dc18-0548. - DOI - PMC - PubMed

Publication types

MeSH terms